Published in final edited form as:

AIDS. 2010 February 20; 24(4): 573–582. doi:10.1097/QAD.0b013e32833433df.

Plasma and Cervical Viral Loads among Ugandan and Zimbabwean Women during Acute and Early HIV-1 Infection

Charles S. Morrison, Korey Demers, Cynthia Kwok, Stanley Bulime, Anne Rinaldi, Marshall Munjoma, Megan Dunbar, Tsungai Chipato, Josaphat Byamugisha, Barbara Van Der Pol, Eric Arts, and Robert A. Salata

Behavioral and Biomedical Research Department, Family Health International, Research Triangle Park, NC, USA (CS Morrison PhD, A Rinaldi BA); Cell and Molecular Biology Graduate Group, University of Pennsylvania School of Medicine, Philadelphia, PA, USA (K Demers BS); Biostatistics Department, Family Health International, Research Triangle Park, NC, USA (C Kwok MSPH); Joint Clinical Research Centre, Kampala, Uganda (S Bulime); Department of Obstetrics and Gynaecology, University of Zimbabwe, Harare, Zimbabwe (M Munjoma MPH, T Chipato MD); Women's Global Health Imperative, Research Triangle Institute, San Francisco, CA, USA (Megan Dunbar DrPH); Faculty of Medicine, Makerere University, Kampala, Uganda (J Byamugisha MBChB, PhD); Behavioral Sciences Program, Indiana University School of Medicine, Indianapolis, IN, USA (B Van Der Pol PhD); Department of Medicine, Case Western Reserve University, Cleveland, OH, USA (E Arts PhD, RA Salata MD)

Introduction

Early HIV infection represents a dynamic period during which infection disseminates from local lymph nodes and HIV viremia initially climbs to very high levels followed by a decline to an equilibrium (viral setpoint). The high viremia levels in peripheral blood during early infection appear associated with high levels of HIV transmission [1]. In addition, the level of viral setpoint is an important predictor of subsequent HIV disease progression [2-4].

While this dynamic period has been well-documented in the peripheral blood, little is known about the dynamic of genital viral loads during early infection (first 6 months). Genital viral loads, the biologic mediator between plasma viral loads and HIV transmission, are important to understand particularly during the early infection period. Two recent studies conducted in men [5] and women [6] have documented high genital viral loads during this period.

However, it is unclear if and when a setpoint is attained in the genital compartment. It is also unclear whether there are modifiable risk factors that influence genital viral loads during the early infection period.

Few studies have examined factors associated with plasma viral setpoint. A study conducted among Kenyan sex workers [7] found that use of the injectable-progestin contraceptive depot-medroxyprogesterone acetate (DMPA) at the time of HIV infection was associated with a higher plasma viral load setpoint while the presence of genital ulcer disease (GUD)

Corresponding Author: Charles S. Morrison, PhD, Family Health International, PO Box 13950, Research Triangle Park, NC, 27709, USA; Phone: 919-544-7040; Fax: 919-544-7261; cmorrison@fhi.org.

Disclaimer: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services or FHI, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

A portion of this data was presented previously at the XVI International AIDS Conference (Toronto, Canada. July 13-18, 2006 abstract # MOPE0275) and the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, California. February 24-29, 2007 abstract # 326).

Conflict of interest statement Barbara Van Der Pol consults for Roche Diagnostics. We declare no other conflicts of interest.

during early HIV infection was associated with higher subsequent plasma viral loads. However, these findings have not been corroborated.

HIV-1 genital shedding among women can be affected by both systemic (pregnancy, hormonal contraceptive use, CD4 lymphocyte levels, plasma viral loads, HAART, HIV-1 subtype) [8-15] and local factors (menstruation, genital inflammation, cervical and vaginal infections, abnormal vaginal flora) [6;8-9;13;16-20]. However, factors associated with HIV-1 genital shedding during early HIV-1 infection have not been reported.

We studied the relationship between plasma and genital HIV viral loads among Ugandan and Zimbabwean women during acute and early (first 6 months) HIV infection and examine factors, including hormonal contraceptive use, that may be associated with plasma and genital viral loads during this period and could impact subsequent HIV-1 disease progression or transmission. Data was drawn from a prospective cohort study of contraception and HIV acquisition – the Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study [21] and a subsequent study conducted among the women who became HIV-infected – the Hormonal Contraception and HIV-1 Genital Shedding and Disease Progression among Women with Primary HIV Infection (GS) Study.

Methods

The research was approved by the institutional review boards of the collaborating institutions. All participants provided written informed consent prior to study participation.

Study Population and Procedures

The study population was drawn from women who enrolled in the GS Study during the period from 2001-2007. The 188 GS Study participants were HIV-infected (with known infection dates), ages 18-45 years, were using either no hormonal method, COCs (low-dose pills containing 30 mcg ethinyl estradiol and 150 mcg of levonorgestrel) or DMPA (150 mg depot-medroxyprogesterone acetate administered quarterly). Women were ineligible for enrollment if they had a hysterectomy, a spontaneous or induced abortion within 10 days of enrollment or were using hormonal contraception besides COCs or DMPA.

GS Study procedures were similar to those previously described for the HC-HIV Study [21]. Briefly, when HC-HIV study participants were notified of their HIV-infection, they were informed about the GS Study. Interested women were scheduled as soon as possible for a GS enrollment visit where informed consent procedures were conducted. At enrollment participants were interviewed in the local language to collect sexual behavior, reproductive health and contraceptive history data. We provided contraceptive, HIV risk reduction and condom use counseling and free contraceptives and condoms. Study clinicians conducted a standardized physical (including pelvic) exam and collected specimens for reproductive tract infections, pregnancy testing, Pap smears, lymphocyte phenotyping and plasma and cervical viral loads. Testing for reproductive tract infection and pregnancy was done as previously described [21]. Participants were treated onsite for vaginal infections; women diagnosed with asymptomatic chlamydia, gonorrhea or syphilis were recalled for treatment.

Follow-up visits were conducted at 4, 8 and 12 weeks following enrollment and at 12-week intervals thereafter. Follow-up procedures were similar to those at enrollment and included testing for all STIs (syphilis testing and Pap smears were conducted every 6 months).

Beginning in 2003, women who developed severe symptoms of HIV infection (WHO clinical stage IV or advanced stage III disease), or who had successive CD4 lymphocyte counts of ≤ 200 cells/mm³ were offered highly active antiretroviral therapy (HAART) and

trimethoprim-sulfamethoxazole (for prophylaxis against bacterial infections). At each study visit participants were provided with daily multivitamins and iron.

Analysis Population and Variable Definition

The analysis population for the calculation of plasma and cervical viral setpoints included 188 Ugandan and Zimbabwean women contributing 1,042 plasma and 813 cervical specimens within 24 months of HIV-1 infection. The analysis population for comparison of plasma and genital viral loads during early infection included 173 women providing 528 plasma specimens and 159 women providing 471 cervical specimens evaluated within 6 months of HIV-1 infection.

HIV PCR was performed on samples from visits prior to HIV seroconversion to establish infection timing [21]. For women whose seroconversion visit was also their first PCR+ visit, HIV-1 infection dates were estimated as the midpoint between this and the previous visit. Because HIV testing was conducted every 12 weeks in the HC-HIV Study, estimated infection date was usually within a 6-week window of the actual infection date. We defined acute infections as those that were serologically negative but HIV PCR+. We estimated acute infections to occur 15 days prior to the first PCR+ visit.

Contraceptive exposure definition varied by analysis. For analyses associated with viral setpoint, exposed women were those using COCs or DMPA between the two study visits where the HIV infection occurred. For the comparison of plasma and genital viral loads, exposed women were those using COC or DMPA during the 12-week period prior to the specimen collection visit. When women switched from DMPA to the non-hormonal (NH) group, we calculated DMPA exposure as 120 days from the last injection.

Viral RNA load determination

We obtained samples for cervical viral loads by inserting a dacron swab into the endocervix and rotating the swab for 3-5 seconds [22]. The swabs were then stored in 1 ml of RNALater at -70° C. Due to the viscosity of RNALater, virus was pelleted by diluting the 500 µl of RNALater to a final volume of 8 ml with RPMI. After centrifugation at 23,600 × G for 3 hours at 4° C, the entire viral pellet was resuspended and viral loads estimated according to the ultrasensitive (lower limit of detection =50 copies/ml) procedure of the Roche Amplicor HIV-1 Monitor Test, version 1.5. Details of this methodology are provided in the Supplementary Methods. Plasma viral loads were also performed using the same Roche Amplicor version 1.5 assay as per the manufacturers' protocol. If plasma viral loads were <400 copies/ml, repeat analyses were performed using the ultrasensitive procedure to obtain a sensitivity of 50 copies/ml. Likewise, plasma was diluted 100-fold and the standard Roche Amplicor 1.5 assay was repeated if the initial viral load was >750,000 copies/ml.

HIV-1 DNA sequencing, subtype determination, and prediction of co-receptor usage

To determine HIV-1 subtypes, DNA was extracted from whole blood using the Qiagen DNA extraction kit (Qiagen Inc, Maryland). The *env* gene was PCR amplified in the C2-V3 region using an external-nested PCR amplification with primer pairs ENV B-ED14 (external) and ENV1-ENV2 (nested) [23]. The primer sequences are provided in Supplementary Table 1. PCR products were purified using the Qiagen PCR purification kit then sequenced using the Beckman Coulter CEQ 8000 sequencer using the ENV1 forward primer. Sequences were analyzed and edited as described in the Supplementary Methods. These HIV-1 sequences are available in Genbank (numbers are currently being obtained).

Statistical Methods

We used the Loess procedure to estimate the mean level and timing of plasma and cervical viral setpoints [24]. A marginal model with generalized estimating equation (GEE) approach (to account for repeated measurements on the same individual) was used to determine the plasma viral setpoint among various exposure groups and to model the association between predictors (the difference in viral setpoint between those with and without a specified characteristic) and plasma HIV-1 viral load within the defined time period.

We used Spearman's correlation coefficient to measure correlation between plasma and genital viral loads. We used marginal models using the GEE approach for hypothesis testing of the comparison of genital viral loads levels over time and to evaluate the impact of covariates on cervical HIV-1 RNA levels during early (≤ 6 months) HIV infection.

Because all Zimbabwean participants with completed subtyping ($n=72$) are subtype C, we imputed subtypes for the remaining 57 Zimbabwean participants. Additionally, 2 Ugandan participants with subtype C infections were dropped from multivariate modeling due to small group size.

Results

Of the 188 Ugandan and Zimbabwean women contributing data to these analyses, 129 (69%) were Zimbabwean and 59 (31%) were Ugandan.

Participant Characteristics at HIV Seroconversion Visit

At HIV seroconversion the median age was 25 years and median education was 10 years (Table 1). About two-thirds of women used hormonal contraception including DMPA (40%) and COCs (30%). Only 4% of women were currently pregnant while 13% currently breastfed. Few participants reported multiple sex partners (3%), commercial sex (2%), or having a new sex partner (4%). One quarter of women reported consistent condom use during the previous 3 months. The prevalence of STIs was high: 13 women (7%) had a chlamydial infection, 24 women (14%) had gonorrhea, 55 (31%) women had bacterial vaginosis and most (85%) were HSV-2 positive.

At the HIV infection visit NH participants were slightly older and more likely to be pregnant than COC or DMPA users (Table 1). NH participants also had higher levels of sexual risk including more commercial sex and a higher number of partners spending nights away from home but also reported more consistent condom use (49%) than HC users (13%). No important differences were found in STI prevalence between contraceptive groups (Table 1).

All Zimbabwean participants had subtype C HIV infections, while 34 Ugandan participants (63%) had subtype A, 18 (33%) had subtype D and 2 (4%) had subtype C infections. A subset of these sequences is presented in a phylogenetic neighbor joining tree (see supplementary materials).

CXCR4-usage or dual tropism was only predicted in four participants at the time of early infection in this cohort [25-26]. Of these four participants, one was subtype A, one subtype D and two were subtype C (both from Zimbabwe).

Analysis of HIV Viral Setpoint

We estimated the population mean HIV-1 plasma viral setpoint to be 4.20 $\log_{10}$ HIV-1 copies/ml (95% CI 4.04, 4.35) at 121 days (95% CI, 91-137) from the HIV infection date (Figure 1). Mean viral load at setpoint for participants with dual tropic virus (4.34 copies/ml) was similar to that for the entire analysis population. The crude mean and standard error

for HIV plasma viral load (from 121 days to 24 months) was 4.17 log₁₀ HIV-1 copies/ml (SE=0.04). Multivariable analysis was used to assess the effect of a variety of factors on the estimated mean setpoint. In multivariable analysis, contraceptive (including COC and DMPA) use, STI (chlamydia and gonorrhea), and sexual risk behaviors at the time of HIV infection were not significantly associated with the plasma viral setpoint (Table 2). Younger age (18-24 years) was associated with a decrease in mean viral setpoint of -0.30 log₁₀ HIV-1 copies/ml (95% CI -0.58, -0.02) compared with older age and subtype D (compared to subtype A) infection was associated with an increase in mean viral setpoint of +0.48 log₁₀ HIV-1 copies/ml (95% CI 0.01, 0.94). Both pregnancy (+0.48 copies/ml) and breastfeeding at the time of infection (+0.54 copies/ml) were also significantly associated with an increase in mean viral setpoint. Following the establishment of the mean plasma viral setpoint, subsequent plasma viral loads increased only slightly (+0.005 log₁₀ HIV-1 copies/ml per month; p=0.24) through 24 months.

We also found a significant difference in the time to mean plasma viral setpoint by HIV-1 subtype. Time to setpoint was fastest for subtype D (100 days; 95% CI 67-109 days) followed by subtype A (139 days; 95% CI 109-157 days) and was slowest for subtype C infections (183 days; 95% CI 152-200 days).

Genital Viral Loads during Early Infection

We observed a direct correlation between HIV-1 cervical and plasma viral RNA levels during early infection (Spearman's $r = 0.47$ $p < .0001$) (Figure 1). We found an equilibrium level or 'setpoint' among genital secretions similar to that in the peripheral blood. The mean cervical setpoint was 1.64 log₁₀ HIV-1 copies/swab (95% CI: 1.46-1.82) and occurred at 174 days (95% CI, 145-194) from the estimated infection date. Similar to plasma viral loads, cervical viral loads were higher during acute infection (mean of 3.01 log₁₀ copies/swab) than during periods 1-2, 2-4 and 4-6 months post-infection (means of 2.30, 2.00, and 1.92 log₁₀ HIV-1 copies/swab; $p=0.03$, $p<0.01$ and $p<0.01$, respectively) (Table 3). Cervical specimens taken 1-2 months after HIV-1 infection had higher mean viral loads than specimens taken 2-4 and 4-6 months from time of infection ($p<0.01$). The comparisons were similar when each country was considered individually. Following the establishment of a setpoint at 174 days post-infection, cervical viral loads did not change significantly (+0.001 log₁₀ HIV-1 copies/swab per month; $p=0.85$) through 24 months.

In multivariable analysis, having a non-viral STI (chlamydia, gonorrhea or trichomoniasis) (+ 0.29 log₁₀ copies/swab; $p=0.03$), a partner spending nights away from home (+ 0.22 log₁₀ copies/swab; $p<0.01$), unprotected sex within 3 days (+ 0.21 log₁₀ copies/swab; $p = 0.06$) and Zimbabwe-subtype C infection (+ 0.26 log₁₀ copies/swab; $p = 0.05$) were associated with increased cervical viral loads (Table 4). The effect of subtype D infection on mean cervical viral load (+ 0.30 log₁₀ copies/swab) was of similar magnitude as subtype C infection but was not statistically significant ($p=0.09$). Greater duration since HIV infection (- 0.11 log₁₀ copies/swab per month; $p < 0.01$) was associated with decreased cervical viral loads. There was no association between DMPA (+ 0.12 log₁₀ copies/swab; $p=0.35$) or COC use (+ 0.08 log₁₀ copies/swab; $p=0.50$) and cervical HIV-1 viral loads. Age, pregnancy, breastfeeding, and genital ulcer disease were also not significantly associated with cervical HIV-1 levels.

We also considered our final multivariate model predicting cervical viral loads adjusted for plasma viral load. Higher plasma viral loads were strongly associated with higher mean cervical loads (+ 0.30 log₁₀ copies/swab; $p = <0.001$) and time since HIV infection remained strongly associated with decreased mean cervical loads (-0.09 log₁₀ copies/swab per month; $p < 0.001$). Having a partner who spent nights away from home also remained associated with higher cervical loads (+ 0.20 log₁₀ copies/swab; $p < 0.01$). However HIV-1 subtype,

non-viral STIs and having unprotected sex within the last 3 days were no longer significantly associated with mean cervical loads. Instead, breastfeeding (+ 0.25 log₁₀ copies/swab; p = 0.04) and the number of coital acts per month (15-29 acts: +0.17 log₁₀ copies/swab; p = 0.04; ≥30 acts: + 0.35 log₁₀ copies/swab; p = 0.18) were associated with higher cervical viral loads.

Discussion

We found that women in Uganda and Zimbabwe established a plasma viral setpoint of 4.20 log₁₀ HIV-1 copies/ml at 121 days and an analogous cervical viral 'setpoint' of 1.64 log₁₀ HIV-1 copies/swab at 174 days from estimated date of HIV-1 infection suggesting that setpoint is achieved later in the genital compartment. Cervical viral loads were strongly correlated with plasma viral loads during the first 6 months of HIV-1 infection (p<.0001) and were significantly higher (0.7-1.1 log₁₀ copies/ml higher) during acute infection than subsequently during the early infection period.

Our findings concerning the level and timing of the plasma viral setpoint are similar to those reported by other studies. For example, a study of 161 sex workers in Mombasa, Kenya reported a median viral setpoint of 4.46 log₁₀ copies/ml attained at 4 months post-infection [7]. A study of high-risk Kenyan men and women found a virus setpoint of 4.60 log₁₀ copies/ml at 209 days post-infection [27]. Similarly, a study among newly HIV-infected adults in the U.S. estimated the viral setpoint at 4.56 log₁₀ copies/ml at 117 day post-infection [24].

We found that subtype D infection, pregnancy and breastfeeding at the time of HIV infection were associated with a higher plasma viral setpoint while young age was associated with a decreased plasma setpoint. These findings concerning predictors of plasma viral setpoint contrast with a previous study conducted among Kenyan sex workers. In that study, DMPA use was associated with a higher viral setpoint (compared with no use of hormonal contraception) but no association was reported between older age, pregnancy, breastfeeding or subtype D infection and plasma viral setpoint [7]. While no other analyses of predictors of viral setpoint exist, several studies have reported on predictors of HIV-1 disease progression. A Zambian study found an increased risk of disease progression (CD4 < 200 cells/mm³ or death) among women using hormonal contraception compared with women randomized to copper IUDs [28]. Conversely, a study of postpartum Kenyan women found no differences in change in plasma viral load or CD4 counts among women initiating COCs or DMPA [29]. Additionally, several studies suggest that older age [30] and subtype D HIV-1 infection [31-34] are associated with more rapid HIV-1 disease progression. On the other hand, most studies conclude that pregnancy, while causing transient CD4 decline, is not associated with more rapid disease progression [35-38].

We found a dynamic in the female genital compartment similar to the plasma viral setpoint - high levels of HIV-1 genital viremia during acute infection falling to a steady-state level at about 6 months. Following the establishment of this 'setpoint,' genital viral loads remained constant up to 2 years post-infection. We are not aware of previous reports of a 'setpoint' in the genital compartment. Most previous studies have not had substantial genital viral load data from the acute and early infection periods. However, while it is well-documented that the plasma viral setpoint is predictive of subsequent disease progression [2-4], the utility of a genital 'setpoint' as a predictor of potential infectivity to a sex partner remains to be established.

Our findings corroborate recent reports of high levels of HIV-1 genital shedding early in infection in both women and men with declining levels thereafter [5-6]. Genital and plasma

viral loads have also been strongly correlated in other studies ($r = 0.4$ to 0.7) [20;39-41]; plasma RNA load is often the factor most strongly associated with genital RNA load in multivariable models [40;42]. However the strong correlation between genital and plasma viral loads has not previously been clearly documented during early infection.

Subtype C infection, non-viral STIs, having a partner who spends nights away from home and recent unprotected sex were associated with higher cervical HIV-1 loads while time since infection was associated with decreased cervical loads. Hormonal contraceptive (COC and DMPA) use was not associated with cervical viral loads during early HIV-1 infection. Our results corroborate the findings of much previous research. For example previous studies have identified non-viral STIs [6;9;40;43], recent unprotected sex and subtype C HIV-1 infection [16] as associated with higher genital viral loads. Our findings that hormonal contraception is not associated with HIV RNA genital shedding also agrees with most (but not all) previous studies suggesting that hormonal contraception appears to be associated with shedding of HIV-infected cells (measured by HIV-1 DNA) but not cell-free virus (measured by HIV-1 RNA) in the female genital tract [8-10;12;15;20]. However, we are unaware of previous research assessing correlates of HIV-1 genital shedding among women during early infection.

Our study has a number of important strengths. The study was prospective with samples for both plasma and cervical viral loads being collected every 12 weeks beginning before HIV infection. We measured HIV infection timing with precision by conducting HIV PCR testing on serial samples that were serologically negative. We accurately measured many variables that were potentially associated with both HIV viral setpoint and genital shedding including hormonal contraceptive use and reproductive tract infections. We also measured viral subtype from women with a variety non-B HIV-1 clades. Finally, we enrolled women seeking family planning services in two sub-Saharan countries. This allows for greater generalizability of study results than a study population drawn from a selected high-risk group (e.g. sex workers).

Our study also had limitations. We used RNAlater for storage media for cervical specimens. This resulted in lower cervical viral load levels than for specimens collected in DMSO (compared at later study visits). We only sequenced the C2-V3 region of env and thus cannot fully explore the issue of recombinant viruses. Also, some women had unprotected sex during the 3 days prior to their study visit and thus measured genital viral loads at these visits could have been a combination of the participant's and her partner's viral load. However, we measured unprotected sex acts in the last 3 days and adjusted for this in our model of cervical viral loads and believe that this improves the accuracy of our estimates of predictors of cervical viral loads (Table 4). Finally, we are unable to address whether a genital viral 'setpoint' is meaningful in terms of long-term transmission risk.

In summary, we found that cervical HIV-1 viral loads were highest during acute infection and then declined up to 6 months post-infection where they appeared to reach a setpoint. Factors associated with a higher plasma viral setpoint included older age, subtype D infection, pregnancy and breastfeeding. Factors associated with higher HIV-1 cervical loads during early infection included non-viral STIs, recent unprotected sex, subtype C infection and shorter duration since infection. Modification of these factors could result in slower disease progression (pregnancy, breastfeeding) or HIV-1 transmission risk (prevention of STI and unprotected sex). However, the prognostic value of a cervical viral setpoint on future transmission risk remains to be established.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

C.S.M. is the study principal investigator and directed the design and analysis of the study and wrote the manuscript draft; K.D., S.B., M.M. and B.V.D.P. planned, supervised, conducted (S.B.) and did quality assurance (B.V.D.P.) for the lab work including managing the lab data in Uganda and Zimbabwe; C.K. conducted the data analysis; A.R. monitored the study sites and performed data management; M.D., J.B. and T.C. are site principal investigators and supervised the study teams in Zimbabwe and Uganda; E.A. is the laboratory co-investigator and designed, tested and supervised the virology assays; R.A.S. is the study co-principal investigator and study clinical consultant; all authors contributed to drafts of the manuscript and approved the final manuscript.

We would like to thank Pai-Lien Chen, PhD for designing the statistical analysis plan and supervising data analysis as well as Immaculate Nankya, MBCHB, Ph.D. for assuming directorship of the Uganda laboratory in K.D.'s absence. We would also like to thank the GS Study participants in Uganda and Zimbabwe for their participation in the Study.

Funding Support: This project has been funded with federal funds from the National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Department of Health and Human Services through a contract with Family Health International (FHI) (Contract Number N01-HD-0-3310).

References

1. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. *J Infect Dis.* 2004; 189(10):1785–92. [PubMed: 15122514]
2. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. *N Engl J Med.* 2001; 344(10):720–5. [PubMed: 11236775]
3. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. *N Engl J Med.* 1996; 334(7):426–31. [PubMed: 8552144]
4. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med.* 1997; 126(12):946–54. [PubMed: 9182471]
5. Pilcher CD, Joaki G, Hoffman IF, Martinson FE, Mapanje C, Stewart PW, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. *AIDS.* 2007; 21(13):1723–30. [PubMed: 17690570]
6. Lavreys L, Baeten JM, Panteleeff DD, Richardson BA, McClelland RS, Chohan V, et al. High levels of cervical HIV-1 RNA during early HIV-1 infection. *AIDS.* 2006; 20(18):2389–90. [PubMed: 17117027]
7. Lavreys L, Baeten JM, Kreiss JK, Richardson BA, Chohan BH, Hassan W, et al. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. *J Infect Dis.* 2004; 189(2):303–11. [PubMed: 14722896]
8. Mostad SB, Overbaugh J, DeVange DM, Welch MJ, Chohan B, Mandaliya K, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. *Lancet.* 1997; 350(9082):922–7. [PubMed: 9314871]
9. Clemetson DB, Moss GB, Willerford DM, Hensel M, Emonyi W, Holmes KK, et al. Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. *JAMA.* 1993; 269(22):2860–4. [PubMed: 8497089]
10. Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. *AIDS.* 2004; 18(2):205–9. [PubMed: 15075537]

11. Kupka R, Msamanga GI, Xu C, Anderson D, Hunter D, Fawzi WW. Relationship between plasma selenium concentrations and lower genital tract levels of HIV-1 RNA and interleukin type 1beta. *Eur J Clin Nutr.* 2007; 61(4):542–7. [PubMed: 17151590]
12. Clark RA, Theall KP, Amedee AM, Dumestre J, Wenthold L, Kissinger PJ. Lack of association between genital tract HIV-1 RNA shedding and hormonal contraceptive use in a cohort of Louisiana women. *Sex Transm Dis.* 2007; 34(11):870–2. [PubMed: 17565332]
13. Coleman JS, Hitti J, Bukusi EA, Mwachari C, Muliro A, Nguti R, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. *AIDS.* 2007; 21(6):755–9. [PubMed: 17413697]
14. John-Stewart GC, Nduati RW, Rousseau CM, Mbori-Ngacha DA, Richardson BA, Rainwater S, et al. Subtype C Is associated with increased vaginal shedding of HIV-1. *J Infect Dis.* 2005; 192(3):492–6. [PubMed: 15995964]
15. Kovacs A, Wasserman SS, Burns D, Wright DJ, Cohn J, Landay A, et al. Determinants of HIV-1 shedding in the genital tract of women. *Lancet.* 2001; 358(9293):1593–601. [PubMed: 11716886]
16. Spinillo A, Zara F, Gardella B, Preti E, Gaia G, Maserati R. Cervical intraepithelial neoplasia and cervicovaginal shedding of human immunodeficiency virus. *Obstet Gynecol.* 2006; 107(2 Pt 1):314–20. [PubMed: 16449118]
17. Spinillo A, Zara F, Gardella B, Preti E, Mainini R, Maserati R. The effect of vaginal candidiasis on the shedding of human immunodeficiency virus in cervicovaginal secretions. *Am J Obstet Gynecol.* 2005; 192(3):774–9. [PubMed: 15746671]
18. Reichelderfer PS, Coombs RW, Wright DJ, Cohn J, Burns DN, Cu-Uvin S, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. *AIDS.* 2000; 14(14):2101–7. [PubMed: 11061650]
19. Benki S, Mostad SB, Richardson BA, Mandaliya K, Kreiss JK, Overbaugh J. Cyclic shedding of HIV-1 RNA in cervical secretions during the menstrual cycle. *J Infect Dis.* 2004; 189(12):2192–201. [PubMed: 15181566]
20. Kreiss J, Willerford DM, Hensel M, Emonyi W, Plummer F, Ndinya-Achola J, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. *J Infect Dis.* 1994; 170(6):1597–601. [PubMed: 7996003]
21. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. *AIDS.* 2007; 21(1):85–95. [PubMed: 17148972]
22. John GC, Sheppard H, Mbori-Ngacha D, Nduati R, Maron D, Reiner M, et al. Comparison of techniques for HIV-1 RNA detection and quantitation in cervicovaginal secretions. *J Acquir Immune Defic Syndr.* 2001; 26(2):170–5. [PubMed: 11242185]
23. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, et al. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses.* 2004; 20(4):355–64. [PubMed: 15157354]
24. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. *Ann Intern Med.* 1998; 128(8):613–20. [PubMed: 9537934]
25. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. *J Virol.* 1991; 65(1):356–63. [PubMed: 1985204]
26. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. *J Virol.* 1992; 66(11):6777–80. [PubMed: 1404617]
27. Richardson BA, Mbori-Ngacha D, Lavreys L, John-Stewart GC, Nduati R, Panteleeff DD, et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. *J Virol.* 2003; 77(12):7120–3. [PubMed: 12768032]
28. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. *Am J Obstet Gynecol.* 2007; 197(2):144–e1-8. [PubMed: 17689627]

29. Richardson BA, Otieno PA, Mbori-Ngacha D, Overbaugh J, Farquhar C, John-Stewart GC. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. *AIDS*. 2007; 21(6):749–53. [PubMed: 17413696]
30. Bonnet F, Thiebaut R, Chene G, Neau D, Pellegrin JL, Mercie P, et al. Determinants of clinical progression in antiretroviral-naïve HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996–2002. *HIV Med*. 2005; 6(3):198–205. [PubMed: 15876287]
31. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. *J Infect Dis*. 2008; 197(5):707–13. [PubMed: 18266607]
32. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. *J Infect Dis*. 2007; 195(8):1177–80. [PubMed: 17357054]
33. Senkaali D, Muwonge R, Morgan D, Yirrell D, Whitworth J, Kaleebu P. The relationship between HIV type 1 disease progression and V3 serotype in a rural Ugandan cohort. *AIDS Res Hum Retroviruses*. 2004; 20(9):932–7. [PubMed: 15585080]
34. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. *J Infect Dis*. 1999; 179(1):68–73. [PubMed: 9841824]
35. Tai JH, Udoji MA, Barkan G, Byrne DW, Rebeiro PF, Byram BR, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. *J Infect Dis*. 2007; 196(7):1044–52. [PubMed: 17763327]
36. Minkoff H, Hershow R, Watts DH, Frederick M, Cheng I, Tuomala R, et al. The relationship of pregnancy to human immunodeficiency virus disease progression. *Am J Obstet Gynecol*. 2003; 189(2):552–9. [PubMed: 14520233]
37. Byamugisha, J.; Haawa, K.; Rwambuya, S.; Morrison, C.; Mmiro, FA.; Mugerwa, R., et al. The effect of pregnancy on CD4 lymphocyte cell counts and percentages in Uganda and Zimbabwe: Results from a longitudinal cohort of primary HIV infection. XVI International AIDS Conference; Toronto, Canada. Aug 13–18, 2006; Abstract no. CDB0550
38. Lieve VP, Shafer LA, Mayanja BN, Whitworth JA, Grosskurth H. Effect of pregnancy on HIV disease progression and survival among women in rural Uganda. *Trop Med Int Health*. 2007; 12(8):920–8. [PubMed: 17697086]
39. Andreoletti L, Chomont N, Gresenguet G, Matta M, de Dieu Longo J, Carreno MP, et al. Independent levels of cell-free and cell-associated human immunodeficiency virus-1 in genital-tract secretions of clinically asymptomatic, treatment-naïve African women. *J Infect Dis*. 2003; 188(4):549–54. [PubMed: 12898442]
40. Cu-Uvin S, Snyder B, Harwell JI, Hogan J, Chibwesha C, Hanley D, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. *J Acquir Immune Defic Syndr*. 2006; 42(5):584–7. [PubMed: 16837866]
41. Hart CE, Lennox JL, Pratt-Palmore M, Wright TC, Schinazi RF, Evans-Strickfaden T, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. *J Infect Dis*. 1999; 179(4):871–82. [PubMed: 10068582]
42. Goulston C, McFarland W, Katzenstein D. Human immunodeficiency virus type 1 RNA shedding in the female genital tract. *J Infect Dis*. 1998; 177(4):1100–3. [PubMed: 9534992]
43. Ghys PD, Fransen K, Diallo MO, Ettiegn-Traore V, Coulibaly IM, Yeboue KM, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. *AIDS*. 1997; 11(12):F85–93. [PubMed: 9342059]

Figure 1.
Plasma and cervical HIV-1 viral load setpoints level and timing

Table 1
Participant characteristics at the HIV infection visit by contraceptive exposure group¹

Characteristic	COC (n=52) n (%) or median (Q1-Q3)	DMPA (n=70) n (%) or median Q1-Q3	Control (n=53) n (%) or median (Q1-Q3)	Total (n=175) n (%) or median (Q1-Q3)	p-value ²
Sociodemographic					
Study Site: Uganda	15 (29)	21 (30)	18 (34)	54 (31)	0.84
Zimbabwe	37 (71)	49 (70)	35 (66)	121 (69)	
Age at seroconversion	25 (23-29)	25 (23-27)	27 (23-30)	25 (23-29)	0.05
Living with partner ³	43 (83)	53 (76)	41 (77)	137 (78)	0.64
Number of years in school ³	10 (8-11)	10 (8-11)	10 (7-11)	10 (8-11)	0.76
Reproductive health and STI history					
Number of lifetime pregnancies ³	2 (1-3)	2 (2-3)	2 (1-3)	2 (1-3)	0.79
Current Pregnancy	0 (0)	1 (1)	6 (11)	7 (4)	0.01
Current breastfeeding	3 (6)	10 (14)	10 (19)	23 (13)	0.12
STI symptoms ^{4,5}	13 (25)	24 (34)	18 (34)	55 (31)	0.49
STI history ^{4,6}	6 (12)	7 (10)	6 (11)	19 (11)	0.96
Sexual risk behavior⁴					
≥2 sex partners	1 (2)	2 (3)	3 (6)	6 (3)	0.67
Commercial sex work	0 (0)	0 (0)	4 (8)	4 (2)	0.01
New sex partner	1 (2)	4 (6)	2 (4)	7 (4)	0.64
Had sex with another man	1 (2)	1 (1)	3 (6)	5 (3)	0.52
Participant behavioral risk ⁷	1 (2)	5 (7)	4 (8)	10 (6)	0.40
Participant sexual behavior with all partners					
Number of Coital Acts ⁸	12 (8-20)	8 (4-13)	10 (6-16)	10 (6-16)	0.01
Coital frequency ⁸ :					
0 – 14	32 (62)	53 (76)	37 (70)	122 (70)	0.22
15 – 29	15 (29)	14 (20)	12 (23)	41 (23)	
30+	5 (10)	3 (4)	4 (8)	12 (7)	
Consistent condom use ⁸	5 (10)	11 (16)	26 (49)	42 (24)	<01
Partner nights away from home (last 30 days)	0 (0-10)	0 (0-14)	7 (0-16)	1 (0-15)	0.12

Characteristic	COC (n=52) n (%) or median (Q1-Q3)	DMPA (n=70) n (%) or median Q1-Q3	Control (n=53) n (%) or median (Q1-Q3)	Total (n=175) n (%) or median (Q1-Q3)	p-value ²
Partner had sex with another woman ^{4, 9}	27 (52)	43 (61)	28 (53)	98 (56)	0.50
Primary partner risk ¹⁰	24 (46)	34 (49)	31 (58)	89 (51)	0.42
Clinical/Laboratory Data					
Positive Chlamydia	6 (12)	5 (7)	2 (4)	13 (7)	0.41
Positive Gonorrhea	7 (13)	10 (14)	7 (13)	24 (14)	0.99
Positive Trichomonas	2 (4)	3 (4)	1 (2)	6 (3)	0.88
Positive BV	15 (29)	22 (31)	18 (34)	55 (31)	0.74
Cervical Ectopy	11 (21)	12 (17)	5 (9)	28 (16)	0.33
GUD	2 (4)	0 (0)	0 (0)	2 (1)	0.17
Abnormal vaginal discharge	23 (44)	35 (50)	30 (57)	88 (50)	0.11
Positive HSV-2	43 (83)	58 (83)	48 (91)	149 (85)	0.57
HIV subtype: A	9 (17)	12 (17)	13 (25)	34 (19)	0.85
C	37 (71)	51 (73)	35 (66)	123 (70)	
D	6 (12)	7 (10)	5 (9)	18 (10)	

¹ Based on consistent contraceptive user

² Cochran-Mantel-Haenszel test for categorical variables and Fisher's Exact test if a cell is < 5; Kruskal Wallis test for continuous variables

³ At HC Screening or Baseline Visit

⁴ In last 3 months

⁵ Includes: abnormal vaginal discharge, genital itching, lower abdominal pain, pain during sex, bleeding between periods

⁶ Includes: genital ulcers/sores, genital warts, PID, positive gonorrhea test, positive syphilis test

⁷ Includes: having multiple partners or new sex partner or engaged in commercial sex work or had sex with another man in the last 3 months

⁸ In a typical month during the last 3 months

⁹ Includes: yes and don't know responses

¹⁰ Includes: partner HIV+ or abnormal discharge from penis or weight loss or partner had commercial sex or partner spent nights away from home

Table 2

Analyses of the effect of predictors at the HIV infection visit on HIV-1 plasma viral setpoint (between 121 days – 24 months)

Variable at seroconversion visit	Unadjusted Analysis ⁷		Adjusted Analysis ⁸	
	Viral set point (95% CI) Log ₁₀ HIV-1 RNA copies/mL ¹ (n=593)	p-value	Viral set point (95% CI) Log ₁₀ HIV-1 RNA copies/mL ¹ (n=565)	p-value
Sociodemographic				
Age < 25 at seroconversion	-0.15 (-0.41, 0.10)	0.25	-0.30 (-0.58, -0.02)	0.04
Country/HIV-1 Subtype				
Uganda: subtype A	Reference		Reference	
subtype C	+1.04 (0.64, 1.45)	<.01	N/A	
Subtype D	+0.44 (0.02, 0.86)	0.04	+0.48 (0.01, 0.94)	0.04
Zimbabwe: subtype C	+0.14 (-0.17, 0.44)	0.38	+0.15 (-0.19, 0.48)	0.38
Consistent Contraceptive Use				
COC	+0.08 (-0.23, 0.39)	0.62	+0.16 (-0.18, 0.51)	0.36
DMPA	+0.12 (-0.18, 0.43)	0.43	+0.10 (-0.22, 0.43)	0.53
Non-hormonal	Reference		Reference	
Reproductive health history¹				
Current pregnancy	+0.15 (-0.26, 0.55)	0.47	+0.48 (0.04, 0.91)	0.03
Current breastfeeding	+0.31 (0.04, 0.58)	0.02	+0.54 (0.19, 0.90)	<.01
STI symptoms ^{2,3}	+0.14 (-0.11, 0.39)	0.27	+0.22 (-0.04, 0.48)	0.10
Sexual risk behavior^{1,2}				
Participant behavioral risk ⁴	+0.18 (-0.41, 0.77)	0.55	+0.19 (-0.44, 0.83)	0.55
Partner had sex with another woman ⁵	+0.10 (-0.16, 0.35)	0.46	+0.11 (-0.18, 0.40)	0.45
Primary partner risk ⁶	+0.01 (-0.24, 0.26)	0.93	-0.10 (-0.40, 0.19)	0.50
Clinical/Laboratory Data¹				
Positive Chlamydia	-0.10 (-0.56, 0.35)	0.65	0.00 (-0.48, 0.48)	0.99
Positive Gonorrhea	-0.17 (-0.48, 0.15)	0.30	-0.25 (-0.62, 0.12)	0.19

¹ Increases (+) and decreases (-) in mean viral setpoint are shown as the fraction of log₁₀ copies/ml that are attributable to the factor

² In the last 3 months

³ Includes: abnormal vaginal discharge, genital itching, lower abdominal pain, pain during sex, bleeding between periods

⁴ Includes: having multiple partners or new sex partner or engaged in commercial sex work or had sex with another man in the last 3 months

⁵ Includes: yes and don't know responses

⁶ Includes: partner HIV+ or abnormal discharge from penis or weight loss or partner had commercial sex or partner spent nights away from home

⁷ The crude mean and standard error for HIV plasma viral load (from 121 days to 24 months) was 4.17 log₁₀ HIV-1 copies/ml (SE=0.04).

⁸ Two Ugandan women with subtype C were excluded from multivariable model

Table 3

Endocervical HIV-1 viral loads by country during acute and early infection

	Uganda			Zimbabwe			Overall		
	N of Women	N of Specimens	Estimated Mean and SE ^I (Log ₁₀)	N of Women	N of Specimens	Estimated Meanand SE ^I (Log ₁₀)	N of Women	N of Specimens	Estimated Meanand SE ^I (Log ₁₀)
Acute Infection	48	10	2.83 (0.46)	111	11	3.09 (0.43)	159	21	3.01 (0.31)
1 – 2 months		37	2.23 (0.15)		92	2.32 (0.09)		129	2.30 (0.08)
>2 – 4 months		83	1.88 (0.10)		110	2.06 (0.09)		193	2.00 (0.07)
>4 – 6 months		47	1.85 (0.09)		81	1.95 (0.08)		128	1.92 (0.06)
	P-value ^I								
Acute vs. 1 - 2 months		0.21			0.08			0.03	
Acute vs. > 2 - 4 months		0.04			0.02			<.01	
Acute vs. >4 - 6 months		0.03			0.01			<.01	
1 – 2 vs. > 2 - 4 months		0.02			0.02			<.01	
>2 – 4 vs. >4 - 6 months		0.68			0.28			0.24	
1 - 2 vs. >4 – 6 months		0.01			<.01			<.01	

[/] Estimated mean and standard error obtained from marginal models using the GEE approach

Table 4

Analyses of the predictor effects of HIV-1 endocervical viral load during early HIV-1 infection (data up to 6 months)

Variable	Unadjusted Analysis ¹		Adjusted Analysis ²	
	Log ₁₀ ERNA copies/mL (95% CI) (n=442) ³	p-value	Log ₁₀ ERNA copies/mL (95% CI) (n=420) ³	p-value
Time-invariant variables				
Age < 25 at seroconversion	-0.05 (-0.27, 0.18)	0.69	-0.05 (-0.25, 0.16)	0.66
Country/ HIV-1 Subtype				
Uganda: subtype A	Reference		Reference	
subtype C	+0.24 (-0.81, 1.29)	0.65	N/A	N/A
subtype D	+0.28 (-0.11, 0.67)	0.16	+0.30 (-0.04, 0.64)	0.09
Zimbabwe: subtype C	+0.22 (-0.07, 0.50)	0.13	+0.26 (-0.01, 0.51)	0.05
Time-varying Contraceptive Use at a particular visit				
Consistent COC	+0.12 (-0.13, 0.37)	0.35	+0.08 (-0.15, 0.31)	0.50
Consistent DMPA	+0.12 (-0.11, 0.36)	0.30	+0.12 (-0.13, 0.36)	0.35
Consistent Non-hormonal	Reference		Reference	
Reproductive health and STI history				
Current pregnancy	+0.01 (-0.71, 0.73)	0.98	-0.04 (-0.51, 0.43)	0.85
Current breastfeeding	+0.29 (-0.17, 0.74)	0.22	+0.25 (-0.05, 0.55)	0.10
STI symptoms ^{4,5}	+0.15 (-0.04, 0.33)	0.12	+0.12 (-0.06, 0.29)	0.18
Sexual risk behavior⁴				
Participant behavioral risk ⁶	+0.12 (-0.34, 0.58)	0.60	+0.22 (-0.19, 0.63)	0.28
Coital frequency: ⁷				
0 – 14	Reference		Reference	
15 – 29	+0.10 (-0.11, 0.32)	0.35	+0.15 (-0.05, 0.34)	0.14
30+	-0.07 (-0.36, 0.23)	0.66	+0.19 (-0.23, 0.60)	0.38
Unprotected sex act in last 3 days ⁸	+0.23 (0.01, 0.45)	0.04	+0.21 (-0.01, 0.44)	0.06
Partner had 1+ nights away from home (last 30 days)	+0.22 (0.06, 0.37)	0.01	+0.22 (0.07, 0.36)	<0.01
Clinical/laboratory Data				
Non-viral STIs ⁹	+0.33 (0.07, 0.58)	0.01	+0.29 (-0.02, 0.56)	0.03
GUD	-0.11 (-0.61, 0.38)	0.66	-0.37 (-0.93, 0.19)	0.19
Time variable				
Time since estimated infection date (in month)	-0.14 (-0.19, -0.09)	<0.01	-0.11 (-0.16, -0.06)	<0.01

¹ The crude mean and standard error for HIV endocervical viral load (data up to 6 months) was 2.10 log₁₀ HIV-1 copies/ml (SE=0.04).

² Two Ugandan women with subtype C were excluded from multivariable model

³ Increases (+) and decreases (-) in mean viral setpoint are shown as the fraction of log₁₀ copies/ml that are attributable to the factor

⁴ In the last 3 months

⁵ Includes: abnormal vaginal discharge, genital itching, lower abdominal pain, pain during sex, bleeding between periods

⁶Includes: having multiple partners or new sex partner or engaged in commercial sex work or had sex with another man in the last 3 months

⁷In a typical month during the last 3 months

⁸Includes: had vaginal intercourse in last 3 days without condom or sperm detected from lab test

⁹Includes: chlamydia, gonorrhea and trichomonas